Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetazolamide in Prevention of Contrast Nephropathy
NCT00634491Phase 2Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Sep 2007
- Primary completion
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of acetazolamide in contrast-induced nephropathy (CIN) (3 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoint: Increased base line creatinine at least 25% at 24 hours. Started Sep 2007; status: completed.
02
Drugs
acetazolamide
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on NCT00634491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00634491.